ArticleBritish journal of cancer2024

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.

Saikat Chowdhury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.